

Fetal-maternal complications due to pregnancy-acquired tuberculosis: a narrative review of the literature

Waleed Razzaq Chaudhry,¹ Sana Altaf,² Cara Mohammed,³ Sofia Fuerte⁴

¹Services Institute of Medical Sciences, Lahore, Pakistan; ²Deccan College of Medical Sciences, Hyderabad, India; ³Sangre Grande Hospital, Trinidad and Tobago; ⁴Tecnológico de Monterrey Campus, Mexico City, Mexico

Abstract

Tuberculosis (TB) during pregnancy can cause certain deleterious effects to both the mother and the fetus, leading to significant morbidity and mortality. The risk of TB rises significantly during pregnancy due to dampening of the immune response in females and certain factors yet to be studied. Since pregnant females are ruled out of clinical trials due to their pregnancy status, not much clinical data is available on how to combat TB in them or about the clinical safety and efficacy of certain drugs. Hence, not only is it important to make pregnant females vital study participants of clinical trials, but also to enhance their knowledge regarding the disease so that they may timely access quality care. It is also important to facilitate these TB-positive pregnant females through the introduction of gender-sensitive policies that are more exclusive and allow access to quality TB control programs that provide timely care, nutritional support, and quality and supportive management.

Key words: tuberculosis, HIV, pregnancy, co-infection, immune response, lack of knowledge.

Correspondence to: Waleed Razzaq Chaudhry, Services Institute of Medical Sciences, Lahore, Pakistan. E-mail: waleedrazzaq101@yahoo.com

Introduction

Among infectious diseases, tuberculosis (TB) is the leading cause of death globally affecting more than 2 million people as reported by the World Health Organization (WHO) in 2018 [1]. As per the latest report by WHO, Europe has the lowest incidence of 231, 000 followed by America. A staggering 4,37 million cases have been reported in Southeast Asia causing it to have the highest incidence [1]. Globally, of the 9.9 million cases of TB, 2.5 million have been reported from Africa alone [1]. The following eight countries totaled two-thirds of the incidence worldwide in 2020, namely India (26%), China (8,5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), Nigeria (4.6%), Bangladesh (3.6%) and South Africa (3.3%) [1]. In the year 2020, women made up 33% of the prevalence of TB, while men and children accounted for 56% and 11%, respectively. An addition of 150,000 cases of TB in 2019 among pregnant females worldwide has further added to the disease burden.

As per WHO reports, 67,500 cases were reported from pregnant women from the Southeast Asian region, which is an alarming figure for the future in terms of the global impact of the disease [2]. TB has a detrimental impact on pregnancy outcomes, both for the mother and the fetus. This is predominantly governed by the site and severity of the disease, response to antituberculous drug therapy, TB complications, gestational age of the fetus at diagnosis, and if the patient has a co-infection with HIV. As a condition itself, pregnancy does not exacerbate the disease susceptibility nor does it influence the progression of the disease from latent to active form [3]. The

epidemiological data regarding TB during pregnancy is scarce [4]. Unfortunately, pregnant women are underrepresented as a part of clinical research data since the status of pregnancy is not stored in any surveillance database. Additionally, pregnant women are routinely excluded from trials [5]. As per estimates by global modeling studies, TB has an incidence of 200,000 cases each year during pregnancy [4].

Etiology of tuberculosis during pregnancy

Limited studies are available that explain the immunological mechanism by which the risk of TB increases during pregnancy. Of what is known, as pregnancy progresses, cells that are part of the cell-mediated immunity (e.g., CD4+/CD8+-T cells) diminish. In contrast, the cells that decrease the immune response (e.g., Treg) tend to rise in number [4]. At the time of pregnancy, the function of CD4+ and CD8+ T-cells also decreases [4]. This immune suppression continues to decrease until it reaches the last point at the time nearing delivery [4]. Such collective changes in the immune response increase the susceptibility to some infections (e.g., *Listeria*) and exacerbate other infections (e.g., influenza). Research conducted in Kenya and India demonstrated that the amount of interferon- γ (IFN- γ) produced after stimulation with *Mycobacterium tuberculosis* (Mtb)-specific antigens decreases at the time of pregnancy compared to post-birth [4]. Pregnant females demonstrate such patterns both in the presence and absence of HIV. Though HIV decreases the production of IFN- γ throughout pregnancy, even in the presence of sufficient CD4+ T-cells [4]. In a study



conducted comprising pregnant women from Kenya and Uganda, the Mtb-specific CD4⁺ polyfunctional response was diminished in late pregnancy irrespective of the HIV status [4]. A study with Indian pregnant female subjects who had gestational diabetes (GDM) was conducted. The patients demonstrated an impaired IFN- γ response to Mtb-specific antigens. Of note, pregnant women with coexisting GDM and HIV had the highest level of impairment [4]. Such an explanation suggests that during pregnancy an impaired cell-mediated immune response may worsen because of underlying co-morbidities like HIV and GDM. This eventually will permit TB to thrive. This warrants further research consisting of pregnant females who have coexisting HIV, GDM, and TB.

Epidemiological data

As per recent epidemiologic data concerning pregnancy, women are more prone to developing TB disease within the first 90 days of their pregnancy as opposed to any other time of their life [4]. A study from the UK followed 192,000 pregnant females who had an incidence rate of TB of 1.95 [95% confidence interval (CI) 1.24-3.07] in their postpartum period as compared to the time when they were not pregnant [4]. Another study from Sweden analyzed 649,000 medical records of women who were in their reproductive years. The researchers observed an escalating incidence of TB during pregnancy (IRR 1.4, 95% CI 1.1-1.7) and 6 months after delivery (IRR 1.9, 95% CI 1.5-2.5) as compared to the times the females were not pregnant [4]. A further, higher incidence of TB along with mortality is reported in females having a history of HIV [4]. Through their study, Miele *et al.* report that TB kills around 500,000 females yearly, with most of them being in their reproductive years [6]. Hence, this further affirms that TB is common during females' reproductive years and is a significant contributor to maternal and childhood mortality.

The WHO provides statistics for South Africa that there was an estimated incidence of 360,00 cases of TB in 2019. As per the WHO, 360,000 cases of TB were reported in South Africa in 2019 with 14,000 individuals suffering from MDR-TB the exact year, at a rate of 615 per 100,000 population. Despite the high burden of TB cases, the publicity given to TB cases in pregnant women was scarce [7]. Sobhy *et al.* conducted a meta-analysis on active TB. They reported an increasing incidence of maternal morbidity [odds ratio (OR) 2.8], antenatal admission (OR 9.6), miscarriage (OR 9.0), anemia (OR 3.9), and cesarean delivery (OR 2.1). In pregnant females who received no treatment for TB, there was an increased rate of preterm delivery (OR 1.7), low birth weight (OR 1.7), fetal distress (OR 2.3), low Apgar score at 1 min (OR 5.7), birth asphyxia (OR 4.6) and perinatal death (OR 4.2) [8]. A large-scale US national cohort study by Dennis *et al.*, comprising 4053 pregnant females with TB, reported alarmingly high rates of severe pre-eclampsia and eclampsia [proportionality ratio (PR) 1.7 and 3.9, respectively], postpartum hemorrhage (PR 1.8), placenta previa (PR 1.9), and sepsis (PR 6.2). The study subjects had a 37 times higher in-hospital mortality rate, compared to females without TB. No racial or ethnic disparities were considered in this study [9], which might be a limitation and is a factor upcoming studies can shed light on.

Additionally, another study by El-Messidi *et al.*, comprising US-based subjects, reported an increasing incidence of concurrent HIV in females having TB [10]. Another study from India by Lewis *et al.* reported an escalating number of cases of anemia, and intrauterine growth restriction in pregnancies with active TB [11]. A study consisting of the Chinese population was reported by Sun *et al.*, which

demonstrated that TB, either in mothers or their partners, led to an increased risk of stillbirths (OR 1.89 and 2.13, respectively) as opposed to individuals without active TB [12].

Challenges in receiving healthcare

The aftermath TB has on a pregnant woman is governed by multiple factors, primarily which organs of the body are affected, the disease's extent, the trimester of pregnancy, the mother's nutritional profile, immune status, and the presence or absence of HIV infection. Lastly, the availability of healthcare facilities for diagnosing and treating TB earlier during the disease course also plays a crucial role in the prognosis [13]. The interplay of social and cultural barriers also has a pivotal role [14], which can cause a delay in seeking care along with a lack of knowledge.

A study comprising infants from Durban, South Africa, whose mothers were suffering from TB, were at increasing risk of contracting the disease as their mothers either had presented late for their antenatal checkups or did not receive adequate prenatal care [15]. Mulondo *et al.* conducted a study in the Limpopo province in South Africa to assess the status of knowledge in pregnant females suffering from TB regarding seeking timely care. The authors reported that the participants had a lack of knowledge regarding late presentation to antenatal care checkups, complications of TB, and its concurrent presentation with HIV [16].

Pregnant females are inadequately represented in medical research, which is primarily because pregnancy is not reported as part of the surveillance data and, secondarily, during clinical trials, pregnant women are routinely excluded as study subjects [17]. The national and international management guidelines for TB management during pregnancy suffer from inconsistencies since the data regarding the clinical safety and efficacy of TB drugs during pregnancy has not been collected or reported systematically [18].

MDR-TB poses another threat during pregnancy since specific treatment options remain scarce. Key medications like aminoglycosides remain a potential threat due to their adverse clinical safety profile, as they can lead to ototoxicity and nephrotoxicity in the fetus. Furthermore, 2nd-line drugs such as ethionamide-prothionamide can lead to teratogenicity. With recent advancements, oral drugs have been recently approved for managing MDR-TB in the US (bedaquiline) and Europe (bedaquiline and delamanid). However, the limited pharmacokinetics data and clinical safety during pregnancy greatly limit their use [18]. A significant proportion of pregnant females with TB face death due to coinfection with HIV. Of note, poor adherence to dual ATT and antiretroviral (ARV) therapy can be the root cause in this subset of the population. Though treatment options exist for managing these co-existing conditions in pregnancy, they can cause increased pill burden, increased adverse effects, and drug-drug interactions [18].

It is well documented and understood that barriers to accessing and utilizing can trigger gaps in treatment control for TB, particularly in countries of South Asia, like India. Such barriers and challenges can not only lead to treatment delay but also increase the transmission of the disease [19]. Challenges at healthcare facilities providing treatment for TB [20], like ill treatment from healthcare workers, dishonest and corrupt systems, lack of flexible timings of the healthcare facilities, and long queues in government hospitals can lead to drug resistance in the longer run [20,21].

In many parts of the world, tradition spearheads the right to access quality care for women. For instance, in India, women to date



are deemed inferior to men, hence reducing their role in making healthcare-related decisions [22]. Women from these cultures are financially dependent to a great extent on their husbands, causing them to acquire permission to seek quality healthcare, which causes delays in seeking treatment [23] and hence medication resistance in the time to follow. Additionally, for women to have TB in these regions is considered a stigma that also impacts and dampens their right to quality care [24].

With 40% emerging cases of TB in India among women and counting, there is an urgent need for stakeholders to develop more gender-sensitive measures for controlling TB, with crucial gaps present in the existing program such as a lack of women healthcare workers, poor nutritional support, and lack of integration with other local bodies like the National Health Mission and Reproductive and Child Health Programme, particularly Maternal Health Services [25]. In light of the aforementioned factors, it is instrumental to mention the study by Mathad *et al.*, where they observed the care given to rifampin-resistant TB-positive pregnant females in the KwaZulu-Natal province, South Africa. In their findings, they document discrimination by healthcare workers toward this patient population [26].

Recommendations and future directions for better healthcare access

To better screen and treat pregnant women with TB, it is vital to design a TB control program that is gender-sensitive, enabling such patients to pave the way through help-seeking barriers [14]. This further mandates an urgent prioritization of TB research in this population to bring forth evidence-based tailor-made strategies [27]. Preventive strategies against TB in conjugation with early TB screening followed by rapid pharmaceutical therapy *via* supportive means can in a nutshell guide the path to healthy parent-child pairs [28]. To further supplement this approach, the primary prevention of HIV is another core step in preventing TB during pregnancy. Due to the co-existing nature of HIV and TB, it is imperative to screen all pregnant women positive for HIV for active TB even when the characteristic signs of the disease are not evident [29].

Another measure of the WHO is isoniazid preventive therapy (IPT), which is focused on curtailing the rate of TB infection in HIV-positive pregnant females. Based on clinical data, it has been concluded that pregnancy should not be a contraindication to receiving IPT. Nonetheless, the decision to administer IPT should be patient-specific based on need and the ideal time of administration based on the trimester and state of pregnancy [30]. Adding data related to pregnancy and the postpartum period into routine surveillance can enhance our understanding of TB prevalence, risk, management, and outcomes. Some other critical gaps in managing TB during pregnancy remain, like the pregnancy-related immunologic changes that affect the susceptibility to TB progression [4].

Conclusions

A collective effort is needed from the healthcare stakeholders and patients to eradicate the global burden of TB during pregnancy. It can be vital to start by educating pregnant females to counter their lack of knowledge regarding the disease and how it can adversely impact them and their fetuses. Further research through large-scale trials with pregnant females with TB as study subjects

can help us better understand the clinical efficacy and safety of certain drugs that may be safe and used for both the mother and the fetus.

References

1. Khoza LB, Mulondo SA, Lebesse RT. Perspectives on pregnant women's educational needs to prevent TB complications during pregnancy and the neonatal period. A qualitative study. *BMC Public Health* 2023;23:1997.
2. Sundaram K, Vajravelu LK. Tuberculosis and its clinical consequences on women's health. *Indian J Tuberc* 2024;71:195-203.
3. Hui SYA, Lao TT. Tuberculosis in pregnancy. *Best Pract Res Clin Obstet Gynaecol* 2022;85:34-44.
4. Mathad JS, Yadav S, Vaidyanathan A, et al. Tuberculosis infection in pregnant people: current practices and research priorities. *Pathogens* 2022;1:1481.
5. Marais BJ, Amanullah F, Gupta A, et al. Tuberculosis in children, adolescents, and women. *Lancet Respir Med* 2020;8:335-7.
6. Miele K, Morris SB, Tepper NK. Tuberculosis in pregnancy. *Obstetric Gynecol* 2020;135:1444-53.
7. Knowledge Hub. The first national TB prevalence survey. South Africa. 2018. Short Report. Available from: [https://knowledge-hub.health.gov.za/elibrary/first-national-tb-prevalence-survey-south-africa-2018#:~:text=South%20Africa%20\(SA\)%20is%20one,for%203%25%20of%20cases%20globally](https://knowledge-hub.health.gov.za/elibrary/first-national-tb-prevalence-survey-south-africa-2018#:~:text=South%20Africa%20(SA)%20is%20one,for%203%25%20of%20cases%20globally).
8. Sobhy S, Babiker Z, Zamora J, et al. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. *BJO G* 2017;124:727-33.
9. Dennis EM, Hao Y, Tamambang M, et al. Tuberculosis during pregnancy in the United States: racial/ethnic disparities in pregnancy complications and in-hospital death. *PLoS One* 2018;13:e0194836.
10. El-Messidi A, Czuzoj-Shulman N, Spence AR, Abenhaim HA. Medical and obstetric outcomes among pregnant women with tuberculosis: a population-based study of 7.8 million births. *Am J Obstet Gynecol* 2016;215:797.e1-e6.
11. Lewis PF, Budhewar AS, Bavdekar NB. Fetomaternal outcome of pregnant women infected with tuberculosis: an analytical study. *J South Asian Feder Obst Gynae* 2021;13:197201.
12. Sun Q, Zhang H, Zhang Y, et al. Increased risk of stillbirth among women whose partner has tuberculosis. *BioMed Res Int* 2021;2021:1837881.
13. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. *Clin Infect Dis* 2012;55:1532-49.
14. McArthur E, Bali S, Khan AA. Socio-cultural and knowledge-based barriers to tuberculosis diagnosis for women in Bhopal, India. *Indian J Community Med* 2016;41:62-4.
15. Adhikari M. Tuberculosis and tuberculosis/HIV co-infection in pregnancy. *Sem Fetal Neonatal Med* 2009;14:234-40.
16. Mulondo SA, Khoza LB, Maputle SM. Factors associated with underutilisation of antenatal care services by pregnant women in Limpopo province, South Africa. *Br J Midwifery* 2020;28:788-95.
17. Gupta A, Hughes MD, Garcia-Prats AJ, et al. Inclusion of key populations in clinical trials of new antituberculosis treatments: current barriers and recommendations for pregnant and



- lactating women, children, and HIV-infected persons. *PLoS Med* 2019;16:e1002882.
18. Gupta A, Mathad JS, Abdel-Rahman SM, et al. Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: consensus statements from an international expert panel. *Clin Infect Dis* 2016;62:761-9.
 19. Sreeramareddy CT, Q in ZZ, Satyanarayana S, et al. Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. *Int J Tuberc Lung Dis* 2014;18:255-66.
 20. Vijay S, Kumar P, Chauhan LS, et al. Risk factors associated with default among new smear positive TB patients treated Under DOTS in India. *PloS One* 2010;5:e10043.
 21. Mukerji R, Turan JM. Challenges in accessing and utilising health services for women accessing DOTS TB services in Kolkata, India. *Glob Public Health* 2020;15:1718-29.
 22. Jejeebhoy SJ, Sathar ZA. Women's autonomy in India and Pakistan: the influence of religion and region. *Popul Dev Rev* 27:687-712.
 23. Krishnan L, Akande T, Shankar AV, et al. Gender-related barriers and delays in accessing tuberculosis diagnostic and treatment services: a systematic review of qualitative studies. *Tuberc Res Treat* 2014;2014:215059.
 24. Courtwright A, Turner AN. Tuberculosis and stigmatization: pathways and interventions. *Public Health Rep* 2010;125:34-42.
 25. StopTB.org. A rapid assessment of gender and tuberculosis in India (2018). Available from: <https://stoptb.org/assets/documents/communities/CRG/TB%20Gender%20Assessment%20India.pdf>.
 26. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. *Clin Infect Dis* 2012;55:1532-49.
 27. Bates M, Ahmed Y, Kapata N, et al. Perspectives on tuberculosis in pregnancy. *Int J Infect Dis* 2015;32:124-7.
 28. Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcome of 38 cases in Lima, Peru. *Clin Infect Dis* 2009;48:1413-9.
 29. Loto OM, Awowole I. Tuberculosis in pregnancy: a review. *J Pregnancy* 2012;2012:379271.
 30. WHO. Guidelines for intensified tuberculosis case finding and isoniazide preventive therapy for people living with HIV in resource-constrained settings. Available from: https://iris.who.int/bitstream/handle/10665/44472/9789241500708_eng.pdf.

Received: 5 July 2024; Accepted: 17 February 2025; Early view: 1 September 2025.

Contributions: Waleed Razzaq Chaudhry: study conceptualization and design, manuscript writing, and editing. Sana Altaf, Cara Mohammed, Sofia Fuerte: manuscript writing and editing of the final draft for approval. All authorships have been assigned as per the ICMJE authorship criteria.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: not applicable.

Informed consent: not applicable.

Patient consent for publication: not applicable.

Availability of data and materials: not applicable.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

